CD11b antibody | 5C6
Rat anti mouse CD11b antibody, clone 5C6 (MCA711) used for the identification of microglia in mixed glial cultures by immunofluorescence.
Image caption:
Murine primary cortical mixed glial culture were treated with LPS (1 μg/ml) and IFNγ (0.5 ng/ml) for 24 hours and immunostained for NOS2 (A, B), GFAP (C) or CD11b (D). A and C show the same field and E is their merged image. B and D show the same field and F is their merged image. In control cultures NOS2-immunoreactive cells were not observed (data not shown). There is (LPS + IFNγ)-induced NOS2 expression in numerous cells (A, B). NOS2-positive cells were almost never GFAP immunoreactive (A, C, E) indicating a lack of NOS2 expression in most astrocytes. In contrast, virtually all NOS2-positive cells (>98%) were identified as microglia by their CD11b immunoreactivity. Nuclei are counterstained with Hoechst 33258 in A-D. NOS2-positive cells were identified with a rabbit anti-NOS2 antibody (1:500, BD Biosciences), GFAP-positive cells with a mouse anti-GFAP antibody (1:1000, Sigma) and CD11b-positive cells with 5C6 mouse anti-CD11b antibody (1:400, Serotec). Bar, 100 μm.
From: Saura J.
Microglial cells in astroglial cultures: a cautionary note.
J Neuroinflammation. 2007 Oct 15;4:26. Review.
This is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to identify microglia in the retinal outer nuclear layer in a murine model of retinitis pigmentosa by immunofluorescence.
Image caption:
Infiltrating microglia phagocytose rods that are immunonegative for markers of early apoptosis and do not phagocytose cones during rod degeneration.
Photoreceptor cones are not phagocytosed by microglia during rod degeneration. (Upper panels) At P21–23, although infiltrating microglia in the ONL (CD11b, green) contain phagocytosed nuclei (DAPI, blue), none of these were found to be associated with cone arrestin immunopositivity (red), despite the close proximity of arrestin-positive cone somata (highlighted by circled area) to infiltrating microglia. (Lower panels) Example of a CD11b-positive microglial cell in the ONL juxtaposed closely to an arrestin-positive soma (highlighted by circled area). Analysis of orthogonal views of the confocal image stack demonstrates the absence of cone phagocytosis by microglia. Scale bar, 10 μm.
From: Zhao L, Zabel MK, Wang X, Ma W, Shah P, Fariss RN, Qian H, Parkhurst CN, Gan WB, Wong WT.
Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration.
EMBO Mol Med. 2015 Jul 2;7(9):1179-97.
This is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody clone 5C6 (MCA711) used to identify macrophages in mixed populations by flow cytometry.
Image caption:
Infiltration of GFP+ BM-cells in infarct and peri-infarct regions. (A-B) Dot plots of viable macrophages/granulocytes (CD11b+CD45high, top right quadrants) and microglia (CD11b+CD45dim, bottom right quadrants) in cortex from BM-chimeric unmanipulated mice and mice exposed to pMCAO. (C) Bar graph showing mean numbers of CD11b+CD45dim microglia and CD11b+CD45high macrophages/granulocytes in BM-chimeric mice 24 hours after pMCAO, subdivided based on expression of GFP (n = 5). Approximately 92% of of the CD45high population were GFP+ . (D) Estimation and comparison of mean numbers of CD11b+CD45dim microglia in non-chimeric (n = 10) versus BM-chimeric mice (n = 5) 24 hours after of pMCAO shows significantly fewer CD11b+CD45dim microglial cells in irradiated mice. (E) Overview, showing distribution of infiltrating GFP+ BM-derived cells into infarct (IF) and peri-infarct (P-IF) regions 24 hours after pMCAO. (E-G) By 24 hours, GFP+ single cells (F) and vessel-associated aggregates of GFP+ cells (arrows in G) were observed in infarct and peri-infarct regions. Some of the vessel-associated cells were round, leukocyte-like cells (arrows) while others were elongated cells lining the vasculature (arrow heads in G and in insert). (H) Bar graph showing mean numbers of single GFP+ cells and vessel-associated aggregates of GFP+ cells in ipsi- and contralateral cortex 24 hours after surgery (n = 10). (I-P) Immunohistochemical staining of CD45.1 (I, K), CD45.2 (J, L), IgG2a (M, O) and CD45 (N, P) in ischemic tissue in BM-chimeric (I, J, M, N) and non-chimeric mice (K, L, O, P) 24 hours after pMCAO. N.D, none detected. Scale bars: 200 μm (A), 10 μm (B, C). 50 μm (I-P) *P<0.05, **P<0.01, and ***P<0.001.
From: Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, Finsen B.
Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice.
J Neuroinflammation. 2008 Oct 23;5:46.
This is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to identify macrophages associated with vessels by immunofluorescence.
Image caption:
BM-derived GFP+ single cells and vessel-associated cells express CD11b. Fluorescence microscopy for GFP combined with immunofluorescence detection of (A) CD11b, (B) vWF and (C) CD31, 24 hours after pMCAO. (A) Fluorescence detection of GFP and CD11b showed that most GFP+ cells co-expressed CD11b (yellow cells, indicated by arrows), and intermingled with CD11b+ host cells. Note also that a few GFP+ cells did not co-express CD11b (arrow head). Insert shows high magnification of GFP+ cells, some of which co-express CD11b, aggregated around a vessel. (B, C) Fluorescence detection of GFP and the endothelial cell markers vWF (B) and CD31 (C). Inserts show higher magnification of sections of the same vessels. Although there are indications that single vWF+ cells co-express GFP (arrows in B), this could not be reproduced using staining for CD31, and the majority of vWF+ and CD31+ cells showed no co-expression of GFP. Instead, GFP remained confined to round and elongated cells located in the juxtavascular space (insert in C). CD11b+ cells were visualized using Alexa Fluor® 568-conjugated goat anti-rat IgG, vWF+ and CD31+ cells using Alexa Fluor® 546-conjugated goat anti-rabbit IgG and Alexa Fluor® 594-conjugated goat anti-rat IgG, respectively. Scale bars: 20 μm (A-C)..
From: Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, Finsen B.
Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice.
J Neuroinflammation. 2008 Oct 23;5:46.
This is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti mouse CD11b antibody, clone 5C6 (MCA711) used to identify microglia in mouse brain by immunofluorescence.
Image caption:
Activation of adult primary microglial cells in wild-type and IL-1 KO mice. (A) Primary microglial cells were obtained from young adult wild-type mice. The cells stain with the microglial marker CD11b, but not with the neuronal and astroglial markers, NeuN and GFAP, respectively. A few cells are stained with the oligodendroglial cell marker, MBP. NC (inset) is the primary antibody-free negative control. The microglial cells (n = 3 each group) were stimulated for 24 hours in the presence of the vehicle alone, or supplemented with IFN&gama; or IL-4 in the presence or absence of IL-1β. Total NO (NOx; B), TNFα (C), arginase specific activity (Arg-1 spe. act.; D) and IGF-1 (E) were determined from the media or cell suspensions. (B) NOx levels increase upon exposure of the cells to IL-1β and in a synergistic manner upon co-treatment of cells with IL-1β and IFNγ, but not when the cotreatment is with IL-4. (C) TNFα levels increase upon exposure of the cells to IFNγ, and further upon co-treatment with IL-1β. Surprisingly, the co-treatment of the cells with IL-4 and IL-1β induced the highest TNFα level among the experimental treatments used. (D) Arg1-specific activity increased significantly upon exposure to IL-4 and further increased when IL-4 and IL-1β were employed together. (E) IGF-1 levels decreased with exposure of the cells to IFNγ and increased in response to IL-4. The response was partially inhibited by cotreatment of the cells with IL-1β. Data are expressed as mean ± SD (n = 3). *: P<0.05, **: P<0.01, ***: P<0.001 compared with the vehicle-treated group in each genotype (one-way ANOVA followed by Dunnett post-hoc test). ANOVA, analysis of variance; IGF-1, insulin-like growth factor.
From: Sato A, Ohtaki H, Tsumuraya T, Song D, Ohara K, Asano M, Iwakura Y, Atsumi T, Shioda S.
Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury.J Neuroinflammation. 2012 Apr 7;9:65..
This is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used for the evaluation of CD11b expression on microglia by immuno-electron microscopy.
Image caption:
Phenotypic characterization of the dark microglia, using immunoperoxidase staining in the CA1 lacunosum‐moleculare of stressed CX3CR1 knockout mice (A–C, F), or a nontransgenic control mouse (D, E). A: Focal staining for GFP in a dark microglial cell (dc) from a CX3CR1‐GFP mouse. In contrast, normal microglia display strong and diffuse immunoreactivity for IBA1 throughout their cytoplasm. B, C: Examples of dark microglia staining for the myeloid cell marker CD11b, which forms CR3 involved in phagocytosis, strongly expressed at the plasma membrane of their processes encircling synaptic elements. D, E: Dark microglia's staining for 4D4, a recently discovered marker of homeostatic microglia, at the extremity of their ramified processes. In contrast, the dark microglia do not stain for P2RY12 (F), another marker of homeostatic microglia that is abundant in microglial processes (m). a = astrocytic process, bl = basal lamina, bv = blood vessel, s = dendritic spine, and t = axon terminals. Asterisks show the extracellular space. Scale bars = 1 μm.
From: Bisht K, Sharma KP, Lecours C, Sánchez MG, El Hajj H, Milior G, Olmos-Alonso A, Gómez-Nicola D, Luheshi G, Vallières L, Branchi I, Maggi L, Limatola C, Butovsky O, Tremblay MÈ.
Dark microglia: A new phenotype predominantly associated with pathological states.
Glia. 2016 May;64(5):826-39.
This is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used for the demonstration of CD11b expressing cells in the brains of mice by immunofluorescence on formalin fixed cryosections.
Image caption:
IGF-1 is expressed in neurons and a subset of microglia in APPswe/PS1ΔE9 Tg mice.
(E) Double immunofluorescence for IGF-1 (green) and CD11b (red), and nuclear staining with DAPI (blue). Co-localization of IGF-1 to CD11b+ microglia is visualized by the punctuate yellow staining, whereas the IGF-1+ fiber-like structures in the plaques remain green. Scale-bar 20μm.
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APP(swe)/PS1(ΔE9) Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to demonstrate microglial distribution in murine brain by immunohistohistochemistry on acetone fixed tissue cryosections.
Image caption:
Kinetics of macrophage and microglia activation in the brain after intracerebral injection of OVA. OVA-immunized mice or non-immunized mice received a unilateral injection of OVA into the striatum and brain tissue was assessed for presence of macrophage activation at day 7, day 14 and day 28. Images in the top panel shows CD11b immuno-reactivity in control non-immunized mice (a) and after 7 days (b), 14 days (c) or 28 days (d) in OVA-immunized mice: CD68 immunoreactivity in the lower panel in control (e) and after 7 days (f), 14 days (g) and 28 days (h) in immunized mice. Representative data of n = 3 per treatment and time point is shown. Scale bar 50 μm
From: Teeling JL, Carare RO, Glennie MJ, Perry VH.
Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.
Acta Neuropathol. 2012 Oct;124(4):479-90.
doi: 10.1007/s00401-012-0995-3.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to demonstrate microglial distribution in murine brain by immunohistohistochemistry on acetone fixed tissue cryosections.
Image caption:
Macrophage and microglia activation in the brain after intracerebral injection of OVA in wild type, C1q−/− mice and Fcγ−/−. Wild type, C1q−/− mice and Fcγ−/− mice on a BALB/c background were immunized against OVA followed by unilateral injection of OVA into the striatum. Macrophage and microglia activation was assessed by immunocytochemistry. Images in the top panel show CD11b immunoreactivity 3 days after intracerebral injection of OVA in OVA-immunized wild type (a), non-immunized wild type (b) or OVA-immunized Fcγ−/− (c) and OVA-immunized C1q−/− (d). Images in the middle panel shows CD68 immunoreactivity 3 days after intracerebral injection of OVA in OVA-immunized wild type (e), non-immunized wild type (f), OVA-immunized Fcγ−/− (g) and OVA-immunized C1q−/− (h). Scale bar 50 μm. In the bottom panel the number of DAB-positive pixels/field (cells and their processes) in the injected hemisphere was quantified as described in “Materials and methods”. Levels of circulating anti-OVA antibodies (IgG1 and IgG2a) were determined by ELISA. Data is expressed as A450/570 values. Closed circle and dotted line represent wild type, closed diamonds represents C1q−/− mice and closed squares represents Fcγ−/− mice. Statistical analysis: One-way ANOVA, Dunnett’s post-test. Data are expressed as mean of n = 3–6 per group. The experiment was performed once
From: Teeling JL, Carare RO, Glennie MJ, Perry VH.
Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.
Acta Neuropathol. 2012 Oct;124(4):479-90.
doi: 10.1007/s00401-012-0995-3.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used for the demonstration of CD11b expressing cells in the brains of mice by immunohistochemistry on formalin fixed cryosections.
Image caption:
Altered microglial distribution in the hippocampus of APPswe/PS1ΔE9 Tg mice. (A) Low magnification panels show changes in CD11b immunoreactivity in the hippocampus of 6-, 12-, 18-, and 24-month-old Tg mice. The hippocampus from 12- and 24-month-old WT mice is shown for comparison.
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APP(swe)/PS1(ΔE9) Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711G) used to label microglia in mouse brain by immunohistochemistry on formalin fixed cryosections.
Image caption:
Altered microglial distribution in the hippocampus of APPswe/PS1ΔE9 Tg mice. (A) Low magnification panels show changes in CD11b immunoreactivity in the hippocampus of 6-, 12-, 18-, and 24-month-old Tg mice. The hippocampus from 12- and 24-month-old WT mice is shown for comparison.
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711G) used to label microglia in mouse brain by immunohistochemistry on formalin fixed cryosections.
Image caption:
Altered microglial distribution in the hippocampus of APPswe/PS1ΔE9 Tg mice. (A) Low magnification panels show changes in CD11b immunoreactivity in the hippocampus of 6-, 12-, 18-, and 24-month-old Tg mice. The hippocampus from 12- and 24-month-old WT mice is shown for comparison.
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711G) used to label microglia in mouse brain by immunohistochemistry on formalin fixed cryosections.
Image caption:
Altered microglial distribution in the hippocampus of APPswe/PS1ΔE9 Tg mice. (A) Low magnification panels show changes in CD11b immunoreactivity in the hippocampus of 6-, 12-, 18-, and 24-month-old Tg mice. The hippocampus from 12- and 24-month-old WT mice is shown for comparison.
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711G) used to label microglia in mouse brain by immunofluorescence on formalin fixed cryosections.
Image caption:
Combined immunofluorescence staining for CD11b and Aβ shows increased CD11b immunoreactivity near Aβ plaques in low magnification images from 18-month-old Tg mice (B). No plaques are observed in age-matched WT mice (B).
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711G) used to label microglia in mouse brain by immunofluorescence on formalin fixed cryosections.
Image caption:
Arrowheads in (C) point to CD11b+ microglia. Microglial cells are clustered around Aβ plaques in Tg mice, but not in WT mice. The photomicrographs in (C) were both obtained in the dentate molecular layer. DG, dentate gyrus. Scale bar: 500 μm (C).
From: Myhre CL, Thygesen C, Villadsen B, Vollerup J, Ilkjær L, Krohn KT, Grebing M, Zhao S, Khan AM, Dissing-Olesen L, Jensen MS, Babcock AA, Finsen B.
Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice.
Front Cell Neurosci. 2019 Jul 30;13:308.
doi: 10.3389/fncel.2019.00308.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to stain CD11+ cells in murine pulmonary tissue by immunofluorescence on cryostat sections.
Image caption:
Effects of FTY720 on I/R-induced CD11b+ cells recruitment in the lung. Representative immunofluorescence-stained sections visualizing CD11b+ cells (green fluorescence) in lung tissues excised from S mice (A) and from I/R mice administered with vehicle (B) or FTY720 3 mg/kg i.v. (C). Images were taken at 63× magnification through the oil immersion objective (scale bar: 25 μm). Sections were counterstained with DAPI for nuclear morphology (blue fluorescence). (D) Ratio of the number of CD11b+ cells divided by the cell total area in sections of lung tissues excised from vehicle-treated S mice (n = 3) and I/R mice administered with the vehicle (Veh) (n = 3) or with FTY720 3 mg/kg i.v. (F 3) (n = 3) (horizontal bar at the median value).
From:Potì F, Giorgio C, Zini I, Nofer JR, Vivo V, Palese S, Ballabeni V, Barocelli E, Bertoni S.
Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury.
Pharmaceuticals (Basel). 2020 Oct 9;13(10):298.
doi: 10.3390/ph13100298.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to demonstrate microglia in mouse brain by immunohistochemistry on cryostat sections.
Image caption:
Crosstalk between CB and TRPV1 inhibits glial activation and expression of proinflammatory cytokines in the SN of MPTP-treated mice in vivo. Mice were intraperitoneally given an injection of PBS or MPTP. All mice intraperitoneally received vehicle as controls or cannabinoid (CB) antagonist (AM251 or AM630; 0.1 mg/kg/day) for 1 day or 3 days at 30 min before capsaicin (C) and 1 hour before MPTP and a single injection of capsaicin (0.5 mg/kg) at 30 min before MPTP.
Photomicrographs of CD11b+ microglia in the SN of MPTP-treated mice in vivo. Mice that received PBS as a control (CON); capsaicin (C); MPTP (M); MPTP and capsaicin (MC); MPTP, capsaicin, and AM251 (MCA2); or MPTP, capsaicin, and AM630 (MCA6) were sacrificed 3 days after the last MPTP injection. Brains were removed and coronal sections (30 μm) were cut using a sliding microtome. Every sixth serial section was selected and immunostained with CD11b antibody for microglia. Insets show higher magnification.
From: Rayul Wi, Young Cheul Chung, Byung Kwan Jin,
Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson’s Disease,
J Immunol Res, 2020, Article ID 5093493, 11 pages.
doi: 10.1155/2020/5093493.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to label microglia in murine retinal tissue by immunofluorescence.
Image caption:
Effect of MMF on microglia in rd10 mice. (A) Immunostaining of CD11b 1:1000 (green) showed that microglia at P22 in rd10 mice treated with MMF beginning at P12 (MMFP12) appeared to be similar to that of c57 mice; they were in an inactive highly-ramified state within the inner retinal layers, as opposed to naïve rd10 mice where infiltrating microglia/macrophages develop an amoeboid morphology and migrate into the outer retina and subretinal space (white arrows).
From: Yang P, Lockard R, Titus H, Hiblar J, Weller K, Wafai D, Weleber RG, Duvoisin RM, Morgans CW, Pennesi ME.
Suppression of cGMP-Dependent Photoreceptor Cytotoxicity With Mycophenolate Is Neuroprotective in Murine Models of Retinitis Pigmentosa.
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):25.
doi: 10.1167/iovs.61.10.25.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to show CD11+ myeloid cells in CNS parenchyma by immunofluorescence.
Image caption:
BBB-EC IL-1 signaling promotes leukocyte migration.
Immunofluorescence analysis of spinal cord tissue at EAE onset showing CD11b+ myeloid cells infiltrating the CNS parenchyma. Spinal cord sections were stained for CD11b (green, in f, scale bar = 50 μm) and DAPI (blue) together with pan-laminin staining (red).
From: Hauptmann J, et al. Interleukin-1 promotes autoimmune neuroinflammation by suppressing endothelial heme oxygenase-1 at the blood-brain barrier.
Acta Neuropathol. 2020 Oct;140(4):549-67.
doi: 10.1007/s00401-020-02187-x.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used to identify microglia in murine dorsal striatum by immunohistochemistry on formalin fixed cryosections.
Image caption:
CD11b+ microglia in the dorsolateral striatum of WT and TG mice. (a) Images showing CD11b+ microglia in WT and TG mice at 3, 8, and 13 months of age. Zoomed images illustrating CD11b+ microglia morphology. (b) Quantification of CD11b+ cell number per view field at 3 months (n= 4 WT, 4 TG); 8 months (n= 3 WT, 2 TG); and 13 months of age (n= 5 WT, 4 TG). Two-tailed student’s t-test: *p<0.05, p**<0.01. Scale bar: 20 μm.
From: Elabi O, Gaceb A, Carlsson R, Padel T, Soylu-Kucharz R, Cortijo I, Li W, Li JY, Paul G. Human α-synuclein overexpression in a mouse model of Parkinson's disease leads to vascular pathology, blood brain barrier leakage and pericyte activation.
Sci Rep. 2021 Jan 13;11(1):1120.
doi: 10.1038/s41598-020-80889-8
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711G) used to show CD11b staining on neuronal/microglial cultures by immunofluorescence.
Image caption:
Nuclear localization of NFE2L2 in neuronal-microglia culture treated with CBE.
Representative immunocytochemistry analysis of SK-N-BE and BV-2 cell lines in monoculture and co-culture, treated with 200 μM CBE or vehicle for 48 hours; cells were co-stained with anti- NFE2L2 (red) and anti-CD11b antibodies (green), and with DAPI (blue).
From: Brunialti E, Villa A, Mekhaeil M, Mornata F, Vegeto E, Maggi A, Di Monte DA, Ciana P.
Inhibition of microglial GBA hampers the microglia-mediated anti-oxidant and protective response in neurons
bioRxiv 2021.01.20.427380;
doi: 10.1101/2021.01.20.427380
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b antibody, clone 5C6 (MCA711) used for the demonstration of microglia in murine brain by immunohistochemistry on acetone fixed cryosections.
Image caption:
T-cell recruitment after immune complex formation. OVA-immunized mice received a unilateral injection of OVA into the striatum and brain tissue was assessed for presence of CD3-positive T cells at 24 h (a), day 7 (b) and day 14 (c) after OVA injection. Non-immunized mice were used as control (d, g). OVA-immunized wild type (e, h) and Fc&gamma−/− (f, I) mice received a unilateral injection of OVA into the striatum and tissue was analysed for CD3 (d, e, f) or CD11b (g, h, I) immunoreactivity at 7 days. Representative data of n = 2–3 per time point are shown. Scale bar 100μm
From: Teeling JL, Carare RO, Glennie MJ, Perry VH.
Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.
Acta Neuropathol. 2012 Oct;124(4):479-90.
doi: 10.1007/s00401-012-0995-3.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD11b:Alexa Fluor® 647
Rat anti Mouse CD11b:FITC
Rat anti Mouse CD11b:Low Endotoxin
Rat anti Mouse CD11b:Pacific Blue®
Rat anti Mouse CD11b
Rat anti Mouse CD11b:RPE
Rat anti Mouse CD11b:RPE-Alexa Fluor® 647
Rat anti Mouse CD11b:RPE-Alexa Fluor® 750
Rat anti Mouse CD11b:Alexa Fluor® 700
Rat anti Mouse CD11b:StarBright Blue 700
Rat anti Mouse CD11b:Amethyst Orange
Rat anti Mouse CD11b:StarBright Violet 440
Rat anti Mouse CD11b:StarBright Violet 515
Rat anti Mouse CD11b:StarBright Violet 610
Rat anti Mouse CD11b:StarBright Violet 670
Rat anti Mouse CD11b:StarBright Violet 570
Rat anti Mouse CD11b:StarBright Violet 710
Rat anti Mouse CD11b:StarBright Violet 790
- Product Type
- Monoclonal Antibody
- Clone
- 5C6
- Isotype
- IgG2b
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA711A647 | F | 100 Tests/1ml |
|
|
| MCA711F | F | 0.1 mg |
|
|
| MCA711FT | F | 25 µg |
|
|
| MCA711EL | C F FN IF IP | 0.5 mg |
|
|
| MCA711PB | F | 100 Tests/1ml |
|
|
| MCA711 | C F IF IP | 1 mg |
|
|
| MCA711G | C F IF IP | 0.25 mg |
|
|
| MCA711GT | C F IF IP | 25 µg |
|
|
| MCA711PE | F | 100 Tests |
|
|
| MCA711P647 | F | 100 Tests |
|
|
| MCA711P750 | F | 100 Tests |
|
|
| MCA711A700 | F | 100 Tests/1ml |
|
|
| MCA711SBB700 | F | 100 Tests/0.5ml |
|
|
| MCA711AMO | F | 0.1 mg |
|
|
| MCA711SBV440 | F | 100 Tests/0.5ml |
|
|
| MCA711SBV515 | F | 100 Tests/0.5ml |
|
|
| MCA711SBV610 | F | 100 Tests/0.5ml |
|
|
| MCA711SBV670 | F | 100 Tests/0.5ml |
|
|
| MCA711SBV570 | F | 100 Tests/0.5ml |
|
|
| MCA711SBV710 | F | 100 Tests/0.5ml |
|
|
| MCA711SBV790 | F | 100 Tests/0.5ml |
|
Rat anti Mouse CD11b antibody, clone 5C6 recognizes CD11b, also known as the integrin alpha M chain. CD11b is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles.
Rat anti Mouse CD11b antibody, clone 5C6 immunoprecipitates a heterodimer of ~165 and ~95 kDa. This clone also exhibits various functional properties, reportedly inhibiting adhesion in vitro and inflammatory recruitment in vivo. Rat anti Mouse CD11b antibody, clone 5C6 also inhibits delayed hypersensitivity, potentiates bacterial infections and inhibits type 1 diabetes.
Rat anti Mouse CD11b antibody, clone 5C6 immunoprecipitates a heterodimer of ~165 and ~95 kDa. This clone also exhibits various functional properties, reportedly inhibiting adhesion in vitro and inflammatory recruitment in vivo. Rat anti Mouse CD11b antibody, clone 5C6 also inhibits delayed hypersensitivity, potentiates bacterial infections and inhibits type 1 diabetes.
Product Details
- Target Species
- Mouse
- Species Cross-Reactivity
-
Target Species Cross Reactivity Human - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG conjugated to Alexa Fluor 647 - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to Pacific Blue - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to RPE-Alexa Fluor 647 - lyophilized
- Product Form
- Purified IgG conjugated to RPE-Alexa Fluor 750 - lyophilized
- Product Form
- Purified IgG conjugated to Alexa Fluor 700 - liquid
- Product Form
- Purified IgG conjugated to StarBright Blue 700 - liquid
- Product Form
- Purified IgG conjugated to Amethyst Orange - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 440 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 515 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 610 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 670 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 570 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 710 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 790 - liquid
- Reconstitution
- Reconstitute with 1 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Reconstitution
- Reconstitute with 1.0 ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Preparation
- Purified IgG prepared by ion exchange chromatography
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- None present
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Carrier Free
- Yes
- Carrier Free
- Yes
- Immunogen
- Thioglycollate-elicited peritoneal macrophages (TPM)
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Fusion Partners
- Spleen cells from AO rats were fused with cells of the Y3 rat myeloma cell line
Storage Information
- Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- Store at -20oC only.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. - Storage
- Store at +4oC.
DO NOT FREEZE
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P05555
- Entrez Gene
- Itgam
- GO Terms
- GO:0001846 opsonin binding
- GO:0004872 receptor activity
- GO:0008305 integrin complex
- GO:0005634 nucleus
- GO:0007159 leukocyte cell-cell adhesion
- GO:0007229 integrin-mediated signaling pathway
- GO:0008201 heparin binding
- GO:0009897 external side of plasma membrane
- GO:0030593 neutrophil chemotaxis
- GO:0043395 heparan sulfate proteoglycan binding
- GO:0045123 cellular extravasation
- GO:0050798 activated T cell proliferation
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Regulatory
- For research purposes only
Applications of CD11b antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | 1/50 | 1/100 | |
| Functional Assays | |||
| Immunofluorescence | |||
| Immunohistology - Frozen | |||
| Immunoprecipitation | |||
| Flow Cytometry | Neat | ||
| Flow Cytometry | 1/100 | ||
| Immunofluorescence | |||
| Immunohistology - Frozen | |||
| Immunoprecipitation | |||
| Flow Cytometry | 1/10 | ||
| Flow Cytometry | Neat | 1/5 | |
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Histology Positive Control Tissue
- Spleen
- Histology Positive Control Tissue
- Spleen
Copyright © 2021 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Rat IgG2b Negative Control:Pacific Blue® | MCA6006PB | F | 100 Tests/1ml |
|
|
| Rat IgG2b Negative Control:RPE-Alexa Fluor® 750 | MCA6006P750 | F | 100 Tests/1ml |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
Product Specific References
References for CD11b antibody
-
Rosen, H. and Gordon, S. (1987) Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo.
J Exp Med. 166: 1685-701. -
Rosen, H. et al. (1989) Antibody to the murine type 3 complement receptor inhibits T lymphocyte-dependent recruitment of myelomonocytic cells in vivo.
J Exp Med. 169: 535-48. -
Devey, L. et al. (2008) Tissue-resident Macrophages protect the Liver From Ischemia Reperfusion Injury via a Heme Oxygenase-1-Dependent mechanism.
Mol Ther. 1: 65-72. -
Khorooshi, R. et al. (2008) NF-kappaB-driven STAT2 and CCL2 expression in astrocytes in response to brain injury.
J Immunol.181: 7284-91. -
Hickman, S.E. et al. (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.
J Neurosci. 28 (33): 8354-60. -
Tysseling, V.M.et al. (2011) SDF1 in the dorsal corticospinal tract promotes CXCR4+ cell migration after spinal cord injury.
J Neuroinflammation. 8:16. -
Wu, T. et al. (2011) Expression and cellular localization of cyclooxygenases and prostaglandin E synthases in the hemorrhagic brain.
J Neuroinflammation. 8:22. -
Basso, A.S. et al. (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.
J Clin Invest. 118: 1532-43. -
Clausen, B.H. et al. (2008) Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice.
J Neuroinflammation. 5: 46. -
Terwel, D. et al. (2011) Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-{alpha} Expression for Microglial A{beta} Phagocytosis.
J Neurosci. 31: 7049-59. -
McDonald, J.U. et al. (2011) In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils.
FASEB J. 25: 1972-82. -
Heydenreich, N. et al. (2012) C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms.
Stroke. 43 (9): 2457-67. -
Sato, A. et al. (2012) Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury.
J Neuroinflammation. 9: 65. -
Carenini, S. et al. (2001) The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0.
J Cell Biol. 152: 301-8. -
Lu, J. et al. (2010) Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-κB pathway activation.
Cereb Cortex. 20: 2540-8. -
Halle, A. et al. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta.
Nat Immunol. 9: 857-65. -
Traka, .M. et al (2010) A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination.
Brain. 133: 3017-29. -
Yamanaka M et al. (2012) PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.
J Neurosci. 32 (48): 17321-31. -
Babcock, A.A. et al. (2015) Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice.
Brain Behav Immun. 48: 86-101. -
Bisht K et al. (2016) Dark microglia: A new phenotype predominantly associated with pathological states.
Glia. Feb 5. [Epub ahead of print] -
Shinohara M et al. (2016) APOE2 eases cognitive decline during aging: clinical and preclinical evaluations.
Ann Neurol. Mar 2. [Epub ahead of print] -
Mencl, S. et al. (2014) FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation.
J Neuroimmunol. 274 (1-2): 125-31. -
Liu, Z. et al. (2016) Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss.
Brain Behav Immun. 51: 131-43. -
Tachibana, M. et al. (2016) Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.
Exp Neurol. 277: 1-9. -
Kami, K. et al. (2016) Histone acetylation in microglia contributes to exercise-induced hypoalgesia in neuropathic pain model mice.
J Pain. Feb 1. pii: S1526-5900(16)00502-2. [Epub ahead of print] -
Sun, H. et al. (2016) Aquaporin-4 mediates communication between astrocyte and microglia: Implications of neuroinflammation in experimental Parkinson's disease.
Neuroscience. 317: 65-75. -
Ye, M. et al. (2016) Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease.
J Neuroinflammation. 13 (1): 10. -
Hristova M et al. (2016) Inhibition of Signal Transducer and Activator of Transcription 3 (STAT3) reduces neonatal hypoxic-ischaemic brain damage.
J Neurochem. 136 (5): 981-994. -
Kaindlstorfer, C. et al. (2015) Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.
Neurotox Res. 28 (3): 185-94. -
Natrajan, M.S. et al. (2015) Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination.
Brain. 138 (Pt 12): 3581-97. -
Zhang, D. & Teng, J. (2016) Nrf2 knockout: The effect on neurological dysfunction and the activation of glial cells of mice after brain injury
Pak. J. Pharm. Sci., Vol.29, No.4(Suppl): 1365-9. -
Crépeaux, G. et al. (2017) Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity.
Toxicology. 375: 48-57. -
Nagai, J. et al. (2016) Inhibition of CRMP2 phosphorylation repairs CNS by regulating neurotrophic and inhibitory responses.
Exp Neurol. 277: 283-95. -
Garcia-Mesa Y et al. (2016) Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system.
J Neurovirol. Nov 21. [Epub ahead of print] -
Rabl R et al. (2017) Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
BMC Neurosci. 18 (1): 22. -
Mittal, A. et al. (2003) CD11b+ cells are the major source of oxidative stress in UV radiation-irradiated skin: possible role in photoaging and photocarcinogenesis.
Photochem Photobiol. 77 (3): 259-64. -
Schuhmann, M.K. et al. (2017) Blocking of platelet glycoprotein receptor Ib reduces "thrombo-inflammation" in mice with acute ischemic stroke.
J Neuroinflammation. 14 (1): 18. -
Laurent, C. et al. (2017) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy.
Brain. 140 (Pt 1): 184-200. -
Lu, Y. et al. (2016) Annexin A10 is involved in the development and maintenance of neuropathic pain in mice.
Neurosci Lett. 631: 1-6. -
Thomsen, M.S. et al. (2017) Synthesis and deposition of basement membrane proteins by primary brain capillary endothelial cells in a murine model of the blood-brain barrier.
J Neurochem. 140 (5): 741-754. -
Pulido-Salgado, M. et al. (2017) Myeloid C/EBPβ deficiency reshapes microglial gene expression and is protective in experimental autoimmune encephalomyelitis.
J Neuroinflammation. 14 (1): 54. -
Paizs, M. et al. (2017) Axotomy Leads to Reduced Calcium Increase and Earlier Termination of CCL2 Release in Spinal Motoneurons with Upregulated Parvalbumin Followed by Decreased Neighboring Microglial Activation.
CNS Neurol Disord Drug Targets. 16 (3): 356-67. -
Myhre, C.L. et al. (2019) Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice.
Front Cell Neurosci. 13: 308. -
Hilla, A.M. et al. (2017) Microglia Are Irrelevant for Neuronal Degeneration and Axon Regeneration after Acute Injury.
J Neurosci. 37 (25): 6113-24. -
Ellman, D.G. et al. (2020) Conditional Ablation of Myeloid TNF Improves Functional Outcome and Decreases Lesion Size after Spinal Cord Injury in Mice.
Cells. 9 (11)Nov 03 [Epub ahead of print]. -
Madore, C. et al. (2020) Essential omega-3 fatty acids tune microglial phagocytosis of synaptic elements in the mouse developing brain.
Nat Commun. 11 (1): 6133. -
Wi, R. et al. (2020) Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
J Immunol Res. 2020: 5093493. -
Potì, F. et al. (2020) Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury.
Pharmaceuticals (Basel). 13 (10) 298. -
Yang, P. et al. (2020) Suppression of cGMP-Dependent Photoreceptor Cytotoxicity With Mycophenolate Is Neuroprotective in Murine Models of Retinitis Pigmentosa.
Invest Ophthalmol Vis Sci. 61 (10): 25. -
Hauptmann, J. et al. (2020) Interleukin-1 promotes autoimmune neuroinflammation by suppressing endothelial heme oxygenase-1 at the blood-brain barrier.
Acta Neuropathol. 140 (4): 549-67. -
Yoshizaki, S. et al. (2021) Microglial inflammation after chronic spinal cord injury is enhanced by reactive astrocytes via the fibronectin/β1 integrin pathway.
J Neuroinflammation. 18 (1): 12. -
Elabi, O. et al. (2021) Human α-synuclein overexpression in a mouse model of Parkinson's disease leads to vascular pathology, blood brain barrier leakage and pericyte activation.
Sci Rep. 11 (1): 1120. -
Bernier, L.P. et al. (2019) Nanoscale Surveillance of the Brain by Microglia via cAMP-Regulated Filopodia.
Cell Rep. 27 (10): 2895-2908.e4. -
Brunialti, E. et al. (2021) Inhibition of microglial GBA hampers the microglia-mediated anti-oxidant and protective response in neurons.
bioRxiv 2021.01.20.427380 [Preprint] -
Hou, L. et al. (2018) Taurine protects noradrenergic locus coeruleus neurons in a mouse Parkinson's disease model by inhibiting microglial M1 polarization.
Amino Acids. 50 (5): 547-556. -
Cope, E.C. et al. (2018) Microglia Play an Active Role in Obesity-Associated Cognitive Decline.
J Neurosci. 38 (41): 8889-904. -
Mouton-Liger, F. et al. (2018) Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop.
Glia. 66 (8): 1736-51. -
Di Benedetto, G. et al. (2019) Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model.
J Neuroinflammation. 16 (1): 166. -
Gomez-Nicola, D. et al. (2019) Measuring Microglial Turnover in the Adult Brain.
Methods Mol Biol. 2034: 207-15.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
Our CD11b (5C6) Antibody has been referenced in >161 publications*
*Based on June 2020 data from CiteAb's antibody search engine.
